Giuseppe Luigi Banna
National Health Service · 439 works · 8,585 citations · h-index 46
Top works
- COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
- Cancer Stem Cell Analysis and Clinical Outcome in Patients with Glioblastoma Multiforme
- How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere
- Anticancer oral therapy: Emerging related issues
- Gut Microbiota and Cancer: From Pathogenesis to Therapy
- First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status
- Tumor Mutation Burden—From Hopes to Doubts
- Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract
- BRCA-1 and BRCA-2 mutations as prognostic factors in clinical practice and genetic counselling
- EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment
- Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis
- TMB or not TMB as a biomarker: That is the question
- Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy
- Management of Germ Cell Tumors During the Outbreak of the Novel Coronavirus Disease-19 Pandemic: A Survey of International Expertise Centers
- Cementoplasty in the management of painful extraspinal bone metastases: our experience
- Neoadjuvant Chemo-Immunotherapy for Early-Stage Non–Small Cell Lung Cancer
- Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%
- Treatments of AIDS-related Kaposi's sarcoma
- KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures
- Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)